The United States Patent and Trademark Office (USPTO) has granted a patent protecting the GENOCORDIA test (U.S. Patent No. 12,467,091). The patent covers the use of Polygenic Risk Scores for predicting disease complications and response to therapy.

This milestone strengthens OPTITHERA’s intellectual property portfolio, developed with CHUM and Les Laboratoires Servier. Patent applications are also pending in Canada, Europe, Australia and China.